Northern Trust’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$903K Buy
192,430
+10,500
+6% +$54.4K ﹤0.01% 3461
2026
Q2
$853K Buy
181,930
+145,993
+406% +$1.08M ﹤0.01% 3527
2026
Q1
$236K Hold
35,937
– – ﹤0.01% 3894
2025
Q4
$207K Buy
35,937
+3,238
+10% +$17.3K ﹤0.01% 3978
2025
Q3
$143K Buy
32,699
+21,912
+203% +$95.5K ﹤0.01% 4060
2025
Q2
$51.5K Buy
10,787
+2
+0% +$12 ﹤0.01% 4229
2025
Q1
$62K Buy
10,785
+4,967
+85% +$30.3K ﹤0.01% 4198
2024
Q4
$46.2K Buy
5,818
+3,418
+142% +$18.9K ﹤0.01% 4265
2024
Q3
$9.8K Hold
2,400
– – ﹤0.01% 4382
2024
Q2
$12K Hold
2,400
– – ﹤0.01% 4366
2024
Q1
$33.1K Buy
+2,400
New +$29.1K ﹤0.01% 4284

Other funds holding UNCY

Northern Trust's UNCY Position: Q3 2026 in Review

Northern Trust increased its Unicycive Therapeutics (UNCY) stake by 5.8% in Q3 2026, buying an estimated $54.4K and bringing the position to 192,430 shares worth $903K. The position accounts for ﹤0.01% of the portfolio, ranked #3461.

Northern Trust first reported a position in UNCY in Q1 2024 and has held it in 11 quarters since. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Northern Trust held 192,430 shares of Unicycive Therapeutics worth $903K as of Q3 2026.
  • Northern Trust bought 10,500 Unicycive Therapeutics shares in Q3 2026, an estimated $54.4K.
  • Unicycive Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q3 2026, its #3461 holding.
  • Northern Trust first reported a position in Unicycive Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.